- Home
- BL vs OGN Comparison
BL vs OGN Comparison
Compare BL & OGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BL
- OGN
- Stock Information
- Founded
- BL 2001
- OGN 1923
- Country
- BL United States
- OGN United States
- Employees
- BL N/A
- OGN N/A
- Industry
- BL Computer Software: Prepackaged Software
- OGN Biotechnology: Pharmaceutical Preparations
- Sector
- BL Technology
- OGN Health Care
- Exchange
- BL Nasdaq
- OGN Nasdaq
- Market Cap
- BL 3.3B
- OGN 2.7B
- IPO Year
- BL 2016
- OGN N/A
- Fundamental
- Price
- BL $57.25
- OGN $6.70
- Analyst Decision
- BL Buy
- OGN Buy
- Analyst Count
- BL 11
- OGN 3
- Target Price
- BL $59.27
- OGN $17.33
- AVG Volume (30 Days)
- BL 1.2M
- OGN 6.8M
- Earning Date
- BL 11-06-2025
- OGN 10-30-2025
- Dividend Yield
- BL N/A
- OGN 1.19%
- EPS Growth
- BL 48.84
- OGN N/A
- EPS
- BL 1.34
- OGN 2.69
- Revenue
- BL $674,325,000.00
- OGN $6,281,000,000.00
- Revenue This Year
- BL $10.43
- OGN N/A
- Revenue Next Year
- BL $8.78
- OGN $0.65
- P/E Ratio
- BL $42.81
- OGN $2.50
- Revenue Growth
- BL 8.00
- OGN N/A
- 52 Week Low
- BL $40.82
- OGN $6.18
- 52 Week High
- BL $66.25
- OGN $18.02
- Technical
- Relative Strength Index (RSI)
- BL 68.60
- OGN 23.34
- Support Level
- BL $56.45
- OGN $6.18
- Resistance Level
- BL $58.45
- OGN $6.93
- Average True Range (ATR)
- BL 2.05
- OGN 0.38
- MACD
- BL 0.70
- OGN -0.27
- Stochastic Oscillator
- BL 82.12
- OGN 14.69
About BL BlackLine Inc.
BlackLine Inc is engaged in providing financial accounting close solutions delivered as Software as a Service (SaaS). The Company's solutions enable its customers to address various aspects of their critical processes, including financial close & consolidation, intercompany accounting, and invoice-to-cash. The majority of the revenue of the company is earned in the United States.
About OGN Organon & Co.
Organon & Co is a science-based pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.